Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a Healthcare company (Biotechnology) with a market capitalization of $230M. The Maz Rating grades it against the other companies in its sector.
Vanda Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.81, Vanda Pharmaceuticals Inc. trades at 1.0x sales and 1.2x book value. Over the last twelve months it generated about $228M of revenue and a net loss of $278M. It runs a gross margin of 92.7%, an operating margin of -77.6% and a net margin of -119.9%. It shows return on equity of -106.9%, return on invested capital of -76.7% and a free cash flow yield of -82.6%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 1.54. Over the past 52 weeks the share price ranged from $3.57 to $9.94, with a beta of 0.73.
Vanda Pharmaceuticals Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 13 Buy, 5 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.